The Federal Trade Commission said Friday that it is suing three drug middlemen, accusing them of inflating insulin prices.
The Federal Trade Commission took action Friday against the nation’s three largest pharmacy benefit managers, accusing the companies of artificially inflating insulin list prices that resulted in ...
FluMist is a nasal spray manufactured by AstraZeneca that has been used to protect against influenza in the United States ...
In 2025, everyone enrolled in Part D will have their annual out-of-pocket drug costs capped at $2,000. In future years, that cap will rise in step with the rate of change in Part D costs.
The agency alleges CVS’s Caremark, Cigna’s Express Scripts and UnitedHealth’s Optum Rx accepted money from drugmakers in ...
The Federal Trade Commission said on Friday that it had taken legal action against the three largest pharmacy benefit ...
The Federal Trade Commission Friday announced it was suing the country's three biggest pharmacy benefit managers, claiming ...
One-hundred-and-14 community pharmacies across Herefordshire andWorcestershire have signed up to support people in certain ...
The Food and Drug Administration on Friday approved the first at-home flu vaccine, a nasal spray that consumers with a ...
Regulators say the nation's largest pharmacy benefit managers are partly to blame for the soaring cost of insulin in the U.S.
The FTC accuses the largest pharmacy benefit manager companies of unfairly boosting prices on prescription drugs.
FTC sues top PBMs for inflating insulin prices, accusing them of rigging competition and hurting patients. Legal action also includes GPOs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback